AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03532880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill 150 mg
Description: Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)
Study NCT03532880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill 200 mg
Description: Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)
Study NCT03532880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill 250 mg
Description: Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)
Study NCT03532880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Pill 300 mg
Description: Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)
Study NCT03532880 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
Study NCT02669199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Description: The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
Study NCT04613999 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ralinepag
Description: Ralinepag will be supplied as 50 mcg round, orange, XR tablets for oral administration.~It is planned that every subject will receive each of the following regimens in the fasted state:~* Regimen A (50 mcg): 1 × 50 mcg ralinepag XR tablet~* Regimen B (100 mcg): 2 × 50 mcg ralinepag XR tablets~* Regimen C (150 mcg): 3 × 50 mcg ralinepag XR tablets Subjects will receive Regimens A, B and C in a sequential manner in consecutive treatment periods. Subjects who have tolerated the IMP in all prior regimens will continue in the study to receive each subsequent dose.
Study NCT02729805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10ml bolus injection of saline followed by intravenous infusion of saline during the operation
Study NCT02729805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.5mg/kg
Description: 0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
Study NCT02729805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.75mg/kg
Description: 0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
Study NCT02289274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203
Description: NVP-1203(eperisone SR + aceclofenac)
Study NCT02289274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eperisone SR tab. + and Airtal tab.
Description: Eperisone SR and aceclofenac
Study NCT00373100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc acetate
Study NCT00373100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03040765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab 60 MG/ML Prefilled Syringe
Description: Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
Study NCT03040765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid 5Mg/Bag 100Ml Inj
Description: Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
Study NCT03046043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulmonary vein isolation
Description: pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
Study NCT03046043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein isolation
Description: pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
Study NCT03046043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Voltage & CFAE guided ablation
Description: In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
Study NCT00431821 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Home-based exercise prescriptions with weekly motivational telephone calls.
Study NCT00431821 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stroke education
Description: Stroke education program with matched attention phone calls
Study NCT02072382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 850mg twice a day for eight weeks
Study NCT02072382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04055987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual biofeedback, auditory feedback and models
Description: The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
Study NCT02302144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance & Strengthening Exercises
Description: Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
Study NCT00685841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 50 mcg QD
Study NCT00685841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 25 mcg BID
Study NCT00685841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 15 mcg BID
Study NCT00685841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol MDI
Description: Salmeterol MDI 42 mcg BID
Study NCT00685841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID MDI
Study NCT04328922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbial transplantation
Description: Capsules of fecal matter solution (feces from healthy donor, glycerol and saline solution)/
Study NCT04328922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsuls
Description: capsules of glycerol and saline (placebo).
Study NCT03752463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOI-A group
Description: DAOI with A dose
Study NCT03752463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOI-B group
Description: DAOI with B dose
Study NCT03752463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOI-C group
Description: DAOI with C dose
Study NCT03752463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT04355663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor program activating therapy
Description: Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
Study NCT04797923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. Treatment: IP chemotherapy + Systemic chemotherapy
Description: 1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
Study NCT04797923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2. Response evaluation after 4 cycles of IP + systemic chemotherapy
Description: 2. Response evaluation after 4 cycles of IP + systemic chemotherapy~* Conversion surgery will be done following diagnostic laparoscopy after 4 cycles of IP + systemic chemotherapy. Additional 4 cycles of IP + systemic chemotherapy wille be done following surgery.~* If surgery is impossible after 4th cycle, four additional cycles of treatment will be done, and convertibility will be evaluated.~* IP chemotherapy should not exceed total of 8 cycles.
Study NCT04355663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vojta's reflex locomotion
Description: Pacients underwent two months' therapy consisted of 16 face-to-face sessions (1 hour, twice a week for two months).
Study NCT04355663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional electric stimulation
Description: Pacients uderwent two months' therapy. They used the whole time Functional electric stimulation during activities of daily living and underwent 2 individual sessions of Motor program activating therapy.
Study NCT00986180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUCYNTA
Description: 50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
Study NCT00986180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR
Description: 5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
Study NCT01130636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
Study NCT02773459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162+capecitabine
Description: In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
Study NCT01580813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
Study NCT01580813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
Study NCT04405895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Diet
Description: Breakfast Diet (3Mdiet) consist on high-energy breakfast and reduced in energy and carbohydrate (CH) dinner. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 3Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 3Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
Study NCT00860119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam sublingual tablet
Description: 1 mg alprazolam sublingual tablet, given as a single dose to each subject
Study NCT00860119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alprazolam oral tablet
Description: 1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
Study NCT03235817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation
Description: The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
Study NCT03235817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Description: The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
Study NCT03235817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure control ventilation
Description: The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
Study NCT04405895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allday Diet
Description: Allday Diet (6Mdiet) consist in 6 small meals: breakfast, lunch and dinner and 3 snacks, with calories and carbohydrates (CH) evenly distributed throughout the day. Participants fasting serum to provide serum to for the in ex-vivo cell studies, will be collected at fasting (8:00), at start (day 0), after 2 weeks and at the end of 6Mdiet intervention (12 weeks). The participants serum is added to culture medium (as serum conditioned medium) to treat during 48 hours the cultured hepatocytes. After 48 hours of serum treatment, the mRNA extraction for the assessment of SIRT1 and Clock Gene expression will be performed at 00:00, 06:00, 12:00 and at 18:00 to assess SIRT1 and the Clock Genes circadian oscillation in hepatocytes. The 6Mdiet efficacy on reducing the overall glycemic excursions is assessed with continuous monitoring system at baseline after 2 weeks month of diet intervention.
Study NCT02195466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV)
Description: 500 mg bid on days 7-14
Study NCT02195466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: 200 mg bid on days 7-14
Study NCT02195466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole (FCZ)
Description: 200 mg loading dose on day 1, followed by 100 mg qd until day 13
Study NCT03097835 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hyper-Diluted Botox
Description: 0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle
Study NCT03097835 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical anesthesia
Description: Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
Study NCT03097835 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 0.9% saline solution
Description: 0.1ml of 0.9% saline solution will be administered to the side of the face
Study NCT01233921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Given IV
Study NCT01233921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01233921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flow cytometry
Description: Correlative studies
Study NCT01233921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01233921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01233921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01233921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT03001661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilapan-S
Description: DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
Study NCT03438214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Continuous infusion
Description: Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L
Study NCT03438214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Intermittent infusion
Description: Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
Study NCT03421158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding
Description: Newborns were breastfed during the procedure
Study NCT02877797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap
Description: cap assisted esophagogastroduodenoscopy
Study NCT03421158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral sucrose
Description: Newborns were given oral sucrose during the procedure
Study NCT03421158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin contact
Description: Newborns were placed in direct contact with their mothers during the procedure
Study NCT03421158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-nutritive sucking
Description: newborns were given a pacifier to suck on during the procedure
Study NCT01483859 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: preoperative liver stiffness measurement
Description: Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
Study NCT03816215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteer experience
Description: Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
Study NCT03001661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
Study NCT02372071 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BiliCare
Description: Two measurements with the BiliCare device
Study NCT04383236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For test subgroups, probiotic lozenges were consecutively administered twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
Study NCT04383236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oracure oral gel
Description: Sixty adult (group A) and 60 children patients (group B) with diagnosis of minor RAS were included. Both groups were divided into two subgroups, AI and BI (test subgroups) and AII and BII (control subgroups). For control subgroups, oracure gel were consecutively applied twice daily, for five days. The size and pain level of ulcers were recorded on treatment days 0, 3 and 5. The outbreak frequency of RAS within 6 months was investigated for all subgroups.
Study NCT01124344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once Daily, 14 days